Background: Candidaemia is a significant cause of morbidity and mortality in infants. The mortality rate ranges between 21% and 76%. Non-albicans Candida (NAC) species are increasing in incidence as well as resistance to azoles. Very low birthweight (VLBW) infants have numerous risk factors which predispose them as a group to invasive candidaemia. Methods:A retrospective case-control study of candidaemia in VLBW infants admitted to the neonatal unit at Charlotte Maxeke Johannesburg Hospital between 1 January 2015 and 31 December 2017 was undertaken. Clinical and demographic characteristics of VLBW infants who developed candidaemia, commonest Candida species, antifungal susceptibility profiles and outcomes (death) were identified. A total of 71 infants with confirmed positive blood cultures for candidaemia from the National Health Laboratory Services database were selected, and each case was allocated 3 controls; the final sample comprised 284 infants.Results: Bacterial sepsis, chronic lung disease, necrotising enterocolitis (NEC) and NEC surgery, other surgery, anaemia and ventilation, all showed a strong association with development of candidaemia in the infants. The most common isolate was Candida parapsilosis (59.1%), followed by Candida albicans (30.9%). The cases of candidaemia overall and NAC isolates increased over the study years. Resistance to azoles by NAC was demonstrated. Mortality was 31.2% and 28.2% in controls and cases, respectively. The difference in death between the two groups was not statistically significant. Conclusions:The study demonstrated an increasing rate of candidaemia, predominance of NAC isolates and increased resistance to azoles. Stricter infection control measures and medical intervention strategies should be implemented.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.